Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its clinical trial application for 9MW3011 Injection used in patients with polycythemia vera was formally approved by the United States Food and Drug Administration (FDA). 

9MW3011 is monoclonal antibody with an innovative target. It is independently developed by Innovation R&D Center of Mabwell in San Diego, U.S., belonging to Category 1 Therapeutic Biological Products. With its target mainly expressed on the surfaces of liver cell membranes, 9MW3011 can upregulate the level of hepcidin expressed by hepatocytes through specific binding, inhibit the absorption and release of iron, and lower the serum iron level, thus regulating the iron homeostasis in vivo.

The clinical trial application for the 9MW3011 Injection has been accepted by NMPA in October. The proposed indications of 9MW3011 include a variety of diseases classified as rare in different regions of the world, such as β-thalassemia, polycythemia vera and other diseases related to iron homeostasis. There are no mature and effective macromolecular drugs for the relevant indications so far. 9MW3011 is expected to be qualified as an orphan drug in the future and become the first-in-class macromolecular drug to regulate iron homeostasis in vivo.